Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28848352 | 0.82 | KDM4E (0.46) | HCAR2NAPRTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL232290 | 0.81 | HCAR2 (0.50) | HCAR2NAPRTSMN1; SMN2MGAMP4HA1 | |
| SCHEMBL29378297 | 0.81 | SMN1; SMN2 (0.48) | HCAR2LMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL915781 | 0.81 | SMN1; SMN2 (0.48) | HCAR2LMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL29365646 | 0.81 | HCAR2 (0.50) | HCAR2NAPRTSMN1; SMN2MGAMP4HA1 | |
| Hydrochloric Acid SCHEMBL7476482 | 0.79 | HCAR2 (0.48) | HCAR2NAPRTSMN1; SMN2MGAMP4HA1 | |
| SCHEMBL4719997 | 0.79 | SMN1; SMN2 (0.47) | HCAR2NAPRTLMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL6988496 | 0.79 | SMN1; SMN2 (0.47) | HCAR2LMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL15391827 | 0.78 | CYP2C9 (0.56) | LMNASMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15391826 | 0.78 | CYP2C9 (0.56) | LMNASMN1; SMN2ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590343-B2 | Corrosion inhibitor composition for magnesium or magnesium alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2020-03-17 | — | — | US | claimed |
| EP-3284847-B1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | HELMHOLTZ ZENTRUM GEESTHACHT (DE) | 2019-01-02 | — | — | EP | claimed |
| EP-3284847-A1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| US-20180044590-A1 | Corrosion Inhibitor Composition for Magnesium or Magnesium Alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2018-02-15 | — | — | US | claimed |
| US-10590343-B2 | Corrosion inhibitor composition for magnesium or magnesium alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2020-03-17 | — | — | US | disclosed |
| EP-3284847-B1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | HELMHOLTZ ZENTRUM GEESTHACHT (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-3284847-A1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20180044590-A1 | Corrosion Inhibitor Composition for Magnesium or Magnesium Alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2018-02-15 | — | — | US | disclosed |
| EP-2861576-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-07-14 | — | — | US | disclosed |
| US-9340537-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVATIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2861576-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013171642-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2044068-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | HCAR2 3472/4885NAPRT 715/4885LMNA 658/4885 |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HCAR2 2993/4885NAPRT 4146/4885LMNA 4457/4885 |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HCAR2 2748/4885NAPRT 4252/4885LMNA 4722/4885 |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | HCAR2 4129/4885NAPRT 4517/4885LMNA 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.